Among the bright spots in the treatment of patients with breast cancer are the successes achieved in the management of HER2-positive disease. And, therapeutic options are continuing to expand, owing to the advent of novel anti-HER2–targeted agents and multitargeted HER2 receptor blockade.
The study calls for changes to reduce health disparities.
Yale Cancer Center researchers have identified a link between lipids and a third of all myelomas, a type of cancer affecting plasma cells.
A team of researchers from Yale School of Public Health and Yale Cancer Center recently published a study in the Journal of Cancer Survivorship that addresses the needs of cancer survivors who are at least nine years beyond an initial diagnosis.
The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center today announced the launch of "JTCC: The Future of Cancer Care," a podcast series featuring in-depth conversations with clinicians and researchers.
New program automates and simplifies processes needed to successfully participate in the Oncology Care Model.
OncLive, a leading digital provider of resources and information to oncology professionals, has added the Johns Hopkins School of Nursing (JHSON) to its Strategic Alliance Partnership program, the latest of more than 65 partners, including other leading cancer centers, nursing schools and oncology network providers around the country.
Gabriel N. Hortobagyi, MD, who has pioneered many clinical advances in the treatment of women with breast cancer, was honored in the Breast Cancer category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.
Although metastatic breast cancer remains incurable for most women, recent research offers important new guidance for clinicians managing patients across the spectrum of advanced disease.
Suresh Ramalingam, MD, professor, Emory School of Medicine, and chief, Medical Oncology, Department of Hematology and Medical Oncology, Emory University, discusses combinations with immunotherapy agents and chemotherapy being investigated as potential treatments for patients with non–small cell lung cancer.
George D. Demetri, MD, whose teamwork approach has helped pave the way for new drugs for hard-to-treat sarcomas, was honored in the Gastrointestinal Cancer category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.
Experimental drugs that alter cell metabolism also halted tumor growth and extended survival in mice with cancers caused by a gene mutated in several types of brain tumors.
Study identifies a potential drug target for inhibiting common radiation-induced fibrosis.
New study shows blood test does better job than current standard test at tracking severity and potential spread of metastatic melanoma.
The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations.
Researchers there have discovered an inherited genetic marker that might provide clinicians with a personalized tool to gauge an individual’s survival and determine which patients require closer monitoring in the years following surgery.
NYU Langone Medical Center first in Northeast to utilize new technology allowing surgeons to destroy only suspicious prostate tissue.
Second-line treatment of metastatic pancreatic cancer proved to be feasible and beneficial, particularly for patients who received nab-paclitaxel in addition to gemcitabine in the first-line setting.
Expression of the apoptosis regulator protein BIM could help predict response to PD-1 blockade in patients with melanoma.
Early diagnosis and early commencement of the most effective treatment available are essential in managing patients with chronic myeloid leukemia, particularly since therapeutic options have expanded and testing technology has advanced.
Michael J. Hennessy Associates, Inc., a full-service health care communications company offering education, research and medical media, introduces The Institute for Value-Based Medicine, a comprehensive online source of timely data, information and perspectives related to value-based medicine.
A potential biomarker to guide chemotherapy for metastatic colorectal cancer failed to stratify patients by progression-free survival or responsiveness to bevacizumab.
Patients with metastatic colorectal cancer (mCRC) had marginal yet inconsistent improvement in clinical outcomes when treated with a three-drug chemotherapy regimen plus bevacizumab compared with a doublet-bevacizumab regimen.
The investigational anti–PD-L1 antibody avelumab demonstrated clinical activity as a second-line and maintenance therapy for patients with unresectable gastric or gastroesophageal junction cancer.
Nearly a quarter of patients with resectable hepatocellular carcinoma experienced major tumor necrosis of greater than or equal to 50% following preoperative treatment with sorafenib.
The immune checkpoint inhibitor nivolumab demonstrated activity in patients with previously treated esophageal cancer.
Today, in his laboratory at Columbia University, Murty Vundavalli, PhD continues working to understand the genetic and epigenetic aspects of cervical cancer in an attempt to elucidate prognostic markers of response to treatment.
The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations.
Thoracic specialist will guide expansion of clinical programs, integrate research into patient care.
Denise Yardley, MD, and Linda Vahdat, MD, explain the phase III METRIC trial and the potential importance of glembatumumab in triple-negative breast cancer.
